𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma

✍ Scribed by Fabio Calabrò; Vito Lorusso; Gerardo Rosati; Luigi Manzione; Luca Frassineti; Teodoro Sava; Eugenio Donato Di Paula; Silvia Alonso; Cora N. Sternberg

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
146 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combined paclitaxel, cisplatin, and etop
Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas
✍ Jacob J. Lokich; Henry Sonneborn; Norwood R. Anderson; Murray M. Bern; Frank V. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 1 views

BACKGROUND. Paclitaxel (T), etoposide (E), and cisplatin (P) are each active in gastric carcinoma, either as single agents or as part of a multidrug regimen. To the authors' knowledge, the combination of these three agents in the treatment of patients with esophageal or gastroesophageal carcinoma ha

Capecitabine in combination with docetax
Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma
✍ Marco Venturini; Antonio Durando; Ornella Garrone; Maria Antonietta Colozza; Ant 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to evaluate the activity and safety of oral capecitabine in combination with docetaxel and epirubicin (TEX) as first‐line treatment for patients with locally advanced/metastatic breast carcinoma. ## METHODS This open‐label, Phase II study

Phase II trial of irinotecan, paclitaxel
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma
✍ Mark A. Socinski; Alan B. Sandler; Valerie K. Israel; Heidi H. Gillenwater; Lang 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 1 views

## Abstract ## BACKGROUND This Phase II multicenter, open‐label, single‐arm study evaluated the efficacy and safety of a three‐drug combination of irinotecan (CPT‐11), paclitaxel, and carboplatin in advanced nonsmall cell lung carcinoma (NSCLC). ## METHODS Patients received repeated 21‐day cycle

A phase II study of gemcitabine and doce
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma
✍ Barbara J. Gitlitz; Carole Baker; Yvonne Chapman; Heather J. Allen; Linda D. Bos 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND The objectives of the current study were to evaluate the safety and efficacy of gemcitabine plus docetaxel in patients with unresectable (Stage T4 or ≥ N1) metastatic or locally advanced transitional cell carcinoma (TCC) of the urothelial tract. ## METHODS A total of 27